|
|
Post by longliner on Jan 31, 2023 17:04:28 GMT -5
Or maybe UTHR has bigger plans that would eliminate this being a problem  Almost every day, the last trade is huge, float continues to rise...  |
|
|
|
Post by hopingandwilling on Jan 31, 2023 17:22:57 GMT -5
This what you state--" they have their own unique pharmaceutical composition." --so if MannKind has a new unique pharmaceutical composition, why are they using the name for the drug that is patent protected? I will await your answer with bated breath!
|
|
|
|
Post by peppy on Jan 31, 2023 17:40:46 GMT -5
|
|
|
|
Post by anderson on Jan 31, 2023 18:18:55 GMT -5
You have confirmed my suggestion--you must read again what you posted---note the following --"pharmaceutical composition"---meaning that MNKD can't use their pharmaceutical composition which is the drug we are posting about. Hmm you are right that pharmaceutical composition it is under patent protection untill february 21, 2024n, but funny how MNKD it is slated for 2025 release. But mango's answer is probably more correct that it is a different formulation of the active ingredient. |
|
|
|
Post by jkendra on Feb 1, 2023 11:41:17 GMT -5
www.advancedsciencenews.com/inhaled-bubbles-help-deliver-drugs-to-the-lungs/Inhaled “bubbles” help deliver drugs to the lungs by Francina Agosti | Jan 30, 2023 For diseases that affect the lungs, the obvious delivery method would be inhalation, but in some cases, such as pulmonary fibrosis — a disease that affects the alveoli in the lungs and causes shortness of breath — this can be easier said than done. Nintedanib is a drug that has been found to be very helpful for its treatment, but when inhaled, it is rapidly diffused to the bloodstream and does not have enough time to act where it’s needed. A study led by scientists from the University of Pennsylvania showed how the use of nanocarriers improves nintedanib retention and distribution in lung cells after drug inhalation. In particular, in the lung’s alveoli, which are small air sacs that allow the exchange of gases, such as oxygen and carbon dioxide, between the lungs and the blood, and which are primarily affected in pulmonary fibrosis. “We loaded nintedanib into [liposome] nanoparticles to deliver it directly to the lung in a highly concentrated form,” said Laura Ferguson, a pulmonary and critical care fellow in the Department of Medicine, Pulmonary, Allergy, and Critical Care Division of the University of Pennsylvania, Philadelphia, US, and first author of the study. “This work is important for potentially changing how the drug is taken by patients.”
|
|
|
|
Post by jkendra on Feb 1, 2023 12:01:07 GMT -5
Liposome nanocarriers for lung diseases
The most exciting finding was that with this methodology, nintedanib remains in the lungs ten times longer than oral intake, the current standard of care. With this promising data, the team plans to test it in a mouse model of pulmonary fibrosis and evaluate its performance in treating the disease and confirming lowered toxicity when compared with oral nintedanib.
The team does not want to stop at nintedanib and pulmonary fibrosis though. “We are excited to continue to develop this drug delivery system for other small molecule drugs and for RNA delivery,” Ferguson added.
This includes treatment of other alveolar diseases, such as pneumonia, acute respiratory distress syndrome (ARDS), and COVID-19-derived pneumonia, to help develop better therapeutic options.
“Many drugs have dose-limiting side effects or such severe side effects that they cannot be taken at all by humans,” said Ferguson. “If drugs can be delivered in a more targeted fashion, like by directly inhaled nanoparticles, treatment for many lung diseases could be improved.”
|
|
|
|
Post by mango on Feb 1, 2023 13:59:12 GMT -5
This what you state--" they have their own unique pharmaceutical composition." --so if MannKind has a new unique pharmaceutical composition, why are they using the name for the drug that is patent protected? I will await your answer with bated breath! The API is not patent protected. MannKind is using the API (that is not patented), along with the patent protected pharmaceutical carrier, FDKP (MannKind’s patented carrier). Thus, no violations of any patent are being made. Hope this helps clear things up for you! |
|
|
|
Post by jkendra on Feb 2, 2023 11:02:01 GMT -5
Would Verona Pharma (VRNA) at ~1.5B valuation be MannKind's biggest competition in the DPI space ? Looks like they have three DPI FDA approvals in the works for COPD, Asthma, Cystic Fibrosis. www.veronapharma.com/ |
|
|
|
Post by Clement on Feb 2, 2023 12:17:00 GMT -5
re: Verona
It appears that the only competition would be against MNKD-301, dornase alfa, for cystic fibrosis.
UTHR, at least for the present, has dropped COPD.
Nothing is in MNKD pipeline for asthma.
|
|
|
|
Post by Thundersnow on Feb 2, 2023 16:00:59 GMT -5
re: Verona It appears that the only competition would be against MNKD-301, dornase alfa, for cystic fibrosis. UTHR, at least for the present, has dropped COPD. Nothing is in MNKD pipeline for asthma. VRNA's CEO said during an investor presentation there's research out there that states patients prefer Nebulizers because there's very little effort in the mechanics of breathing. He said with DPI there's a technique (ie hand coordination) in administering the drug and can cause problems. He said patients like the simplicity of nebulizers. If that's the case then why are they developing DPI Drugs? He also said Nebulizers have a higher pricing point. He said Nebulizers are priced between $1,100 - $1,200 a month vs. DPI at $500 a month. |
|
|
|
Post by Clement on Feb 2, 2023 16:06:04 GMT -5
re: Verona It appears that the only competition would be against MNKD-301, dornase alfa, for cystic fibrosis. UTHR, at least for the present, has dropped COPD. Nothing is in MNKD pipeline for asthma. VRNA's CEO said during an investor presentation there's research out there that states patients prefer Nebulizers because there's very little effort in the mechanics of breathing. He said with DPI there's a technique (ie hand coordination) in administering the drug and can cause problems. He said patients like the simplicity of nebulizers. If that's the case then why are they developing DPI Drugs?  Check out the BREEZE study where patients found the MNKD inhaler much more convenient than nebulizer. |
|
|
|
Post by Thundersnow on Feb 2, 2023 19:19:11 GMT -5
VRNA's CEO said during an investor presentation there's research out there that states patients prefer Nebulizers because there's very little effort in the mechanics of breathing. He said with DPI there's a technique (ie hand coordination) in administering the drug and can cause problems. He said patients like the simplicity of nebulizers. If that's the case then why are they developing DPI Drugs? Check out the BREEZE study where patients found the MNKD inhaler much more convenient than nebulizer. I'm not arguing with you. I've been in MNKD for over 10 years. I was just repeating what the Verona CEO said. |
|
|
|
Post by uvula on Feb 3, 2023 11:04:16 GMT -5
This is a minor point, but a nebulizer costs real money and a mannkind whistle is probably a few cents.
|
|
|
|
Post by JEvans on Feb 3, 2023 13:00:20 GMT -5
Also, doesn't a nebuliser breathing treatment take 5-10 minutes to complete a single treatment ?
|
|
|
|
Post by uvula on Feb 3, 2023 13:05:54 GMT -5
Also, doesn't a nebuliser breathing treatment take 5-10 minutes to complete a single treatment ? And you can't throw it in your purse and use it anywhere you want. The advantages to not needing a nebulizer could be much bigger than I initially thought. |
|
